Artal Group S.A. Cerevel Therapeutics Holdings, Inc. Transaction History

Artal Group S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$20.27 - $42.44 $33.1 Million - $69.3 Million	-1,633,817 Reduced 99.69%	5,041 $214,000
Q2 2023 Aug 11, 2023	SELL	$23.9 - $35.38 $6.59 Million - $9.75 Million	-275,608 Reduced 14.4%	1,638,858 $52.1 Million
Q1 2023 May 12, 2023	BUY	$22.82 - $35.32 $330,114 - $510,939	14,466 Added 0.76%	1,914,466 $46.7 Million
Q4 2022 Feb 13, 2023	SELL	$25.35 - $31.96 $2.54 Million - $3.2 Million	-100,000 Reduced 5.0%	1,900,000 $59.9 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $12.8 Million - $20.7 Million	500,000 Added 33.33%	2,000,000 $56.5 Million
Q4 2021 Feb 11, 2022	SELL	$29.21 - $44.64 $8.76 Million - $13.4 Million	-300,000 Reduced 16.67%	1,500,000 $48.6 Million
Q3 2021 Nov 12, 2021	SELL	$21.26 - $38.85 $4.25 Million - $7.77 Million	-200,000 Reduced 10.0%	1,800,000 $53.1 Million
Q2 2021 Aug 13, 2021	SELL	$12.56 - $29.69 $6.28 Million - $14.8 Million	-500,000 Reduced 20.0%	2,000,000 $51.2 Million
Q1 2021 May 14, 2021	BUY	$12.37 - $17.74 $2.7 Million - $3.87 Million	217,900 Added 9.55%	2,500,000 $34.3 Million
Q4 2020 Feb 11, 2021	BUY	$9.82 - $18.27 $22.4 Million - $41.7 Million	2,282,100 New	2,282,100 $37.8 Million

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.